Option chain shows key data for Clene's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Clene.

Clene (NASDAQ:CLNN) Stock, Option Chain

Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVGO

BLMZ

BOWL

CLNN

EAST

FFIE

GWRE

HOTH

SIFY

SWBI

TDUP

WHLR

Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket

Gold bar and nugget

Earnings

Eurozone

Commodities

Intraday Update

BDRX

ETWO

Gold Rises Sharply; Methode Electronics Shares Spike Higher

Indianapolis,-,Circa,July,2019:,Conagra,Brands,Manufacturing,Plant.,Conagra

ASNS

ASTH

BRCC

BSFC

CGBS

CING

IGMS

ISPC

KZIA

LGVN

LNTH

LUCY

MSTR

NAAS

OKYO

POOL

QURE

RBBN

RNLX

SOUN

TBIO

TERN

VLCN

VRPX

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Clene Inc

Press Releases

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Health Care

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Financing

Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility

Clene to Present at Upcoming October Conferences

Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Events

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Annovis Bio

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

bluebird bio

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Generation Bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

LakeShore Biopharma Co., Ltd - Ordinary Shares

LakeShore Biopharma

Lantern Pharma

OS Therapies

Ovid Therapeutics

Pluri

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

RenovoRx

Spero Therapeutics

Surrozen

Tenaya Therapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

HC Wainwright & Co.

D. Boral Capital

Benchmark

Canaccord Genuity

EF Hutton

Comments

Clene

Clene (CLNN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga